Form 4: Definium CFO Granted 150,000 Restricted Stock Units

Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts was granted 150,000 restricted stock units, vesting quarterly starting June 2026.

Summary

• Brandi Roberts, Chief Financial Officer of Definium Therapeutics, Inc. (DFTX), was granted 150,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one common share of the Issuer.
• The RSUs will vest in 16 equal quarterly installments, commencing on June 1, 2026.
• Vesting is contingent upon Ms. Roberts providing continuous service to the Issuer on each vesting date.
• The transaction date for this grant was February 3, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting a standard executive compensation practice aimed at retaining key talent and aligning management incentives with long-term shareholder value.

Positives

• The grant of 150,000 restricted stock units to the Chief Financial Officer serves as a significant incentive for long-term retention and aligns management's interests with shareholder value.
• Equity compensation is a common and effective way to motivate key executives.

Negatives

• The future issuance of 150,000 common shares upon vesting of the RSUs will result in a minor dilutive effect for existing shareholders.

Risks

• The vesting of RSUs is subject to the reporting person providing continuous service, meaning the benefit is contingent on continued employment.
• The value of the RSUs upon vesting is dependent on the future market price of Definium Therapeutics, Inc. common shares.

Future Outlook

The vesting schedule for the restricted stock units extends over four years, indicating a long-term incentive structure for the Chief Financial Officer, aligning her future compensation with the company's sustained performance.

Management Comments

• "These shares represent restricted stock units ('RSUs'). Each RSU represents a contingent right to receive one common share of the Issuer."
• "The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."

Industry Context

StockSavvy.ai notes that the grant of restricted stock units to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries, aiming to retain key talent and incentivize long-term performance. This aligns Definium Therapeutics with common executive compensation strategies seen across its peer group.

Comparison to Industry Standards

• Equity compensation, particularly through restricted stock units, is a prevalent practice for executive retention and motivation across various industries, including technology and healthcare.
• Companies like Pfizer, Johnson & Johnson, and Moderna frequently utilize RSU grants as a core component of their executive compensation packages, often with multi-year vesting schedules similar to Definium's 16 quarterly installments.
• The grant size of 150,000 units for a CFO is within the typical range for a company of Definium's likely stage and market capitalization, comparable to grants observed at emerging biotech firms.

Corporate Governance

Related Party Transactions

• The grant of 150,000 restricted stock units to Brandi Roberts, the Chief Financial Officer, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also improved executive retention and alignment of interests.
• Employees: Signals the company's commitment to executive compensation and potentially sets a precedent for other key personnel.
• Management: Provides a significant long-term incentive and compensation component for the Chief Financial Officer.

Next Steps

• The restricted stock units will begin vesting in 16 equal quarterly installments starting June 1, 2026.
• Brandi Roberts will continue to file necessary SEC forms (e.g., Forms 3, 4, 5, 144) as required by the Power of Attorney.

Key Dates

Recommendation

The filing details a routine executive compensation grant, which is a standard practice for talent retention and alignment. It does not present new information that would significantly alter the company's fundamental valuation or strategic direction, thus a 'hold' recommendation is appropriate as it maintains the current investment stance.

Keywords

Definium Therapeutics, DFTX, Brandi Roberts, CFO, Restricted Stock Units, RSUs, Equity Compensation, Executive Compensation, SEC Form 4, Insider Transaction, Stock Grant